Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant encorafenib + binimetinib versus placebo in resected stage IIB/C BRAF V600E/K melanoma
NL-OMON52293Phase 3Active, not recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in cutaneous melanoma (CM) comparing Encorafenib + binimetinib with Placebo (2 arms). Primary endpoints: Safety and tolerability: adverse events and serious adverse events, Safety assessments and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON52293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52293.